None listed
Conditions
Interventions
Procedure/Surgery : Individuals who voluntarily sign the informed consent form and meet the selection criteria have been enrolled in this clinical study. Test subjects are randomly assigned to the exp
Sponsors
Yonsei University Health System, Dental Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Periodonally healthy adult men and women aged 18 years or older 2. Good oral hygiene (plaque index <25% in the entire jaw) (O'Leary et al. 1972) 3. The level of inflammation control is adequate (bleeding on probing of the anterior jaw <25%) (Ainamo & Bay 1975) 4. Those who need to place 1 or 2 implants in the edentulous area where 1 or 2-3 teeth are continuously lost 5. A person who has one or more dehiscence defects of 3 mm or more in the apico-coronal direction around the fixture after implant placement 6. A person who can achieve sufficient fixation during implant placement (determined during implant surgery) 7. If more than 3 months have passed since tooth extraction 8. Cases where soft tissue transplantation is not required after implant placement
Exclusion criteria
Exclusion criteria: 1. A person who has undergone hard tissue or soft tissue transplantation within the last 6 months 2. Those who smoke more than 10 cigarettes a day 3. Drugs that cause soft tissue hypertrophy (e.g., diuretics, immunosuppressants, antiepileptics) or drugs that interfere with bone formation (e.g., corticosteroids) within 2 weeks of screening, or may be taken during the clinical trial person with 4. Those who have administered oral or injection rheumatism treatment within 2 weeks from the time of screening 5. Patients with uncontrolled diabetes or hypertension 6. Those with skin diseases or lesions in the oral cavity (e.g., erosive lichen planus, erosive lichen planus, stomatitis, ulcers, malignant tumors) 7. Those suffering from systemic diseases related to bone metabolism such as osteomyelitis 8. Those who have been or are currently taking oral or injectable bisphosphonate medicines for osteoporosis for more than 3 months (However, according to AAOMS, those who have stopped taking medication for more than 3 months and have CTx level of 0.150ng/ml or higher participate in clinical research) possible) 9. Those who have a history of tumor removal at the surgical site 10. Subjects with Full Mouth Plaque Score and Full Mouth Bleeding Score of 25% or higher 11. A person with an apical or purulent apical lesion on an adjacent tooth 12. Those who lack oral hygiene management skills 13. Those who have received radiation therapy or chemical therapy under the diagnosis of a malignant tumor within the past 5 years 14. Persons with mental illness that significantly affects this clinical trial 15. Pregnant or Nursing Mothers 16. In addition to the above, those who have clinically significant findings that are considered inappropriate for this study as determined medically by the principal investigator or person in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| implant survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Plaque index (PI) (Silness and Loe, 1964 (Silness & Loe 1964)). The four sides of the adjacent tooth and implant are evaluated as 0-3 points.;Probe pocket depth (PPD) of adjacent teeth is measured at 6 locations (mesiobuccal, buccal medial, distal buccal, distal lingual, distal lingual, mesial lingual) using a UNC-15 periodontal probe with a force of 0.2-0.3 N. (Examiner M.H. was calibrated in advance).;Bleeding Index on Probing (BOP);Width of keratinized gingiva (mm);Evaluation of hard tissue changes in the bone defect area using radiographic methods;Evaluation of changes in buccal soft tissue volume around implants through intraoral scan;OHIP-14 | — |
Countries
Korea, Republic of
Contacts
Public ContactJOO YEON LEE
Yonsei University Health System, Dental Hospital
Outcome results
None listed